Albutein
Biological
Grifols Therapeutics LLC
Total Payments
$12.0M
Transactions
1,673
Doctors
193
Companies
5
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.0M | 108 | 4 |
| 2023 | $899,626 | 116 | 11 |
| 2022 | $1.7M | 227 | 32 |
| 2021 | $591,671 | 102 | 7 |
| 2020 | $1.3M | 218 | 32 |
| 2019 | $1.5M | 267 | 40 |
| 2018 | $2.0M | 121 | 17 |
| 2017 | $3.0M | 514 | 106 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11.4M | 1,037 | 95.2% |
| Consulting Fee | $371,710 | 114 | 3.1% |
| Travel and Lodging | $87,977 | 237 | 0.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $54,467 | 20 | 0.5% |
| Honoraria | $37,138 | 5 | 0.3% |
| Food and Beverage | $21,450 | 259 | 0.2% |
| Education | $3,000 | 1 | 0.0% |
Payments by Type
Research
$11.4M
1,037 transactions
General
$575,742
636 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Prevention of Mortality With Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites | Grifols Therapeutics LLC | $2.0M | 0 |
| Pilot Study to Evaluate the Efficacy and Safety of Plasma Exchange With Albutein 5 in Patients With Amyotrophic Lateral Sclerosis | Grifols Therapeutics LLC | $1.8M | 0 |
| A Multicenter, Randomized, Controlled Study To Evaluate The Efficacy and Safety of Short-Term Plasma Exchange Followed by Long-Term Plasmapheresis With Infusion of Human Albumin Combined With Intravenous Immunoglobulin In Patients With Mild-Moderate AD | Grifols Biologicals LLC | $1.8M | 0 |
| Effects of Plasma Exchange With Human Serum Albumin 5 PE-A 5 on Short-term Survival in Subjects With Acute-On-Chronic Liver Failure ACLF at High Risk of Hospital Mortality | Grifols Therapeutics LLC | $1.4M | 0 |
| Pilot Study to Evaluate the Efficacy and Safety of Plasma Exchange With Albutein 5 in Patients With Amyotrophic Lateral Sclerosis | Grifols Biologicals LLC | $1.2M | 0 |
| Effects of Plasma Exchange With Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects With 'Acute-On-Chronic Liver Failure' (ACLF) at High Risk of Hospital Mortality | Grifols Therapeutics LLC | $592,094 | 0 |
| Effects of Plasma Exchange With Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects With Acute-On-Chronic Liver Failure (ACLF) at High Risk of Hospital Mortality. | Grifols Therapeutics LLC | $490,547 | 0 |
| A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin IVIG Plus Standard Medical Treatment SMT Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the In | Grifols Therapeutics LLC | $480,856 | 0 |
| HEAL-LAST: Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement | Grifols Shared Services North America, Inc. | $300,494 | 0 |
| A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor Human Plus Standard Medical Treatment SMT Versus Placebo Plus SMT in Hospitalized Subjects With | Grifols Therapeutics LLC | $291,279 | 0 |
| Hepatic Encephalopathy and Albumin Study HEAL Study | Grifols Shared Services North America, Inc. | $192,389 | 0 |
| Fluid mobilization in hospitalized patients with acute kidney injury | Grifols Shared Services North America, Inc. | $119,033 | 0 |
| Prevention of Mortality With Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites | Grifols Biologicals LLC | $102,369 | 0 |
| Albumin assisted diuresis in patients with cirrhosis decompensated by ascites and peripheral edema, a proof-of-concept double blind randomized trial | Grifols Shared Services North America, Inc. | $101,982 | 0 |
| Prospective multi-center study of infections in cirrhosis | Grifols Shared Services North America, Inc. | $100,000 | 0 |
| Effects of Plasma Exchange With Human Serum Albumin 5 PE-A 5 on Short-term Survival in Subjects With Acute-On-Chronic Liver Failure ACLF at High Risk of Hospital Mortality | Grifols Biologicals LLC | $62,804 | 0 |
| A Multi-Center, Parallel, Double-Blinded, PlaceboControlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFYplus Standard Medical Treatment Compared to Placebo plus Standard Medical Treatment to Prevent Infections in Patients with Hypogammaglobulinemia and RecurrentorSevereInfections Associated with B-cell Chronic Lymphocytic Leukemia | Grifols Therapeutics LLC | $58,980 | 0 |
| Hyperchloremic Metabolic Acidosis in Critically ill Patients and the clinical outcomes of fluid resuscitation | Grifols Shared Services North America, Inc. | $44,051 | 0 |
| Effects of Plasma Exchange With Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects With Acute-On-Chronic Liver Failure (ACLF) at High Risk of Hospital Mortality. | Grifols Biologicals LLC | $26,285 | 0 |
| A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human)plus Standard Medical Treatment (SMT) versus Placebo plus SMT in Hospitalized Subjects with COVID-19 | Grifols Therapeutics LLC | $16,064 | 0 |
Top Doctors Receiving Payments for Albutein
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | San Diego, CA | $11.4M | 1,039 |
| , M.D., M.P.H | Anesthesiology | Springfield, MA | $106,400 | 12 |
| , MD, PHD | Blood Banking & Transfusion Medicine | Lebanon, NH | $63,575 | 41 |
| , M.D | Pulmonary Disease | Atlanta, GA | $28,969 | 10 |
| , MD | Neurology | Bronx, NY | $27,763 | 2 |
| , MD | Hepatology | New Orleans, LA | $17,740 | 22 |
| , MD | Gastroenterology | Richmond, VA | $14,061 | 14 |
| , MD | Neurology | Sun City, AZ | $10,920 | 15 |
| , M.D | Gastroenterology | Austin, TX | $10,494 | 28 |
| , M.D | Anesthesiology | Richmond, VA | $9,708 | 3 |
| , MD | Internal Medicine | Coronado, CA | $9,449 | 13 |
| , M.D | Geriatric Psychiatry | New York, NY | $9,071 | 12 |
| , M.D | Neurology | New York, NY | $8,863 | 11 |
| , MD | Geriatric Psychiatry | Rochester, NY | $8,795 | 9 |
| , MD | Transplant Surgery | Dallas, TX | $8,788 | 5 |
| , MD, MPH | Gastroenterology | Dallas, TX | $8,704 | 11 |
| , M.D | Critical Care Medicine | Atlanta, GA | $7,917 | 12 |
| , M.D | Hepatology | San Clemente, CA | $7,742 | 7 |
| , MD | Specialist | Pittsburgh, PA | $7,532 | 16 |
| , MD | Neurology | Las Vegas, NV | $7,143 | 7 |
| , M.D | Internal Medicine | Los Angeles, CA | $7,000 | 1 |
| , MD | Neurology | Boston, MA | $6,771 | 5 |
| , MD | Obstetrics & Gynecology | Gainesville, GA | $6,568 | 2 |
| , MD PHD | Neurological Surgery | Boston, MA | $6,427 | 7 |
| , M.D | Nephrology | Buffalo, NY | $5,511 | 11 |
Ad
Manufacturing Companies
- Grifols Therapeutics LLC $7.2M
- Grifols Biologicals LLC $3.2M
- Grifols Shared Services North America, Inc. $1.5M
- Grifols USA, LLC $59,302
- Grifols, S.A. $30,406
Product Information
- Type Biological
- Total Payments $12.0M
- Total Doctors 193
- Transactions 1,673
About Albutein
Albutein is a biological associated with $12.0M in payments to 193 healthcare providers, recorded across 1,673 transactions in the CMS Open Payments database. The primary manufacturer is Grifols Therapeutics LLC.
Payment data is available from 2017 to 2024. In 2024, $1.0M was paid across 108 transactions to 4 doctors.
The most common payment nature for Albutein is "Unspecified" ($11.4M, 95.2% of total).
Albutein is associated with 20 research studies, including "Prevention of Mortality With Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites" ($2.0M).